Preliminary analysis indicates vaccine efficacy of 51 percent among children younger than 2 years and 37 percent among children 2 to 5 years
FDA Advisers Weigh COVID-19 Booster Shots for Fall
Vaccine experts still guessing at what the ever-changing pandemic will bring
FDA Panel Meets to Craft Future Vaccine Strategy
No official vote is planned, and no specific vaccine products will be discussed
U.S. Senate Narrowly Confirms Califf to Head FDA
Califf briefly served as FDA commissioner toward the end of President Barack Obama’s administration
Many COVID-19 Home Test Users May Act on Quarantine Inappropriately
Users may fail to quarantine or quarantine unnecessarily because of misinterpretation of pretest probability
Senate Committee Backs Califf Nomination to Head FDA
Among those who voted against Califf’s nomination were Democrats who expressed concerns about his links to pharmaceutical companies
Most COVID-19-Related EUAs Not Supported by High-Quality Evidence
Most EUAs were for diagnostic products; most supported by comparisons with previously authorized assays, analytical in vitro studies
FDA May Allow Pfizer Boosters for 12- to 15-Year-Olds by Monday
Agency also expected to reduce the amount of time adolescents and adults must wait between their second dose of vaccine and booster
FDA Approves Pfizer Pill as First At-Home COVID-19 Treatment
Recent trial showed Paxlovid cut the odds for hospitalization and death by nearly 90 percent in high-risk people
FDA Approves Pfizer Boosters for Teens Aged 16 to 17
Pfizer first sought the approval for using the boosters in this age group at the end of November